Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who cares let him believe that, he will miss out on a great opportunity. You know Warren Buffet's saying
"The Stock market is a device for transferring money from the impatient to the patient"
Those who hang in here will be greatly rewarded. The other poster though, well he will miss out on a good opportunity to make money.
Yes and thank you. You are correct! RXII should have some news for us hopefully soon. Would like to see what kind of merger they can come up with
Wrong. totally wrong. Who told you this nonsense?
Of course he says that. He has to keep Gerald coming back for more dilution. The truth is that Josh Sason can care less about Amarantus. His company dumps shares the minute they get them to make money, that's how those operations work.
The lower the stock goes, the more shares Amarantus has to give up to obtain funding. Magna on the other hand makes money even at .02 cents or .03 cents doesn't matter they are still in the green when they are diluting shares of Amarantus. It's the shareholders that lose.
I hope so, I guess the company is working on resolving the M&A they have been pretty quiet for now. We shall find out soon enough what goes down. I hope Rxi management can find a way to redeem themselves and build shareholder value for those people holding for a few years now.
Ibalizumab is close on intravenous administration for HIV. That means once approved patients will have to go to the hospital twice a month and stay there for a few hours to get intravenous administration. Ibalizumab is not even close to self injection like PRO 140. Matter of fact I don't even believe they are yet in a phase 2 trial for self injection. I will have to go back and look that up.
PRO 140 will be leaps and bounds ahead anyways even if it comes out later. Patients will want to do their treatment at home, very quick. Who wants t hassle traveling to the hospital every time you need treatment? Nice try on the Ibalizumb argument but maybe next time try harder.
Especially in an HIV market. That's like saying the market for NASH is $6 bil but so and so company can only make peak sales of $1 bil. The market opportunity for the taking is what it is.
In the case of HIV the company told you what it is. $11 billion for monotherapy, and $5 billion for adjunct therapy.
As for competition I don't think investors in CYDY need to worry. Ibalzumab from that taiwan company is a treatment that must be done twice a monoth through an IV in a hospital. Pro 140 you can inject at home. I would think people would probably not want to drive to the hospital everytime they need HIV treatment. Taking pills everyday is already a hassle, having to drive to the hospital just to get treatment I would think is worse.
Pro 140 is the given go to choice.
Well they said most results 2nd half. so preliminary data on eye study, skin scarring, and samcyprone should come by July/August/September IMO. We shall wait and see what company says soon. Also waiting on merger talk!
Totally wrong. no way its only peak sales of $1.28 billion. The market for adjunct therapy is $5 billion and the monotherapy is $11 billion.
oh Man I'm sorry for your losses, but its gonna be hard to recoupe your losses anyways. When did you buy may I ask? If it was before the first reverse split, the stock would have to trade at least $1,600 per share for a shareholder to break even. Plus now they want to do another reverse split to be voted on June 6. I hope you recovered your losses in another stock.
The problem is that GC's father is on the BOD. Unless he plans to fire his own son it is not going to happen. That's the problem when you have family members in corporations, they can never be run properly because of nepotism.
Data was good and actually AVXL was climbing after the uplist to the NASDAQ. The problem with AVXL wasn't the data its that Adam F wrote a damaging article which caused a mass panic sell by investors. It went from being $10 per share to where it is now because of the negative article. If he writes a negative article on the biotech stock (adam F.) his cronies help short the stock at the same time making good coin. That's why AVXL dipped. If not for that negative article I think AVXL would be trading higher.
If both the HIV and HIV adjunct therapy are successful and approved by the FDA I can see a hefty market cap of $11 billion. But with our current float that wouldn't equate to $500 per share. Depends if a reverse split is eventually done or not. then it could be possible
Not guaranteed but IMO if the phase 2b monotherapy results of PRO 140 are very good at the conference they present at with Gilead. I expect either a partnership or buyout. Again it not guaranteed but a huge possibility. You have to remember these big pharma's like to protect their major IP.
If PRO 140 gets to market it will eat into Gilead's revenue stream big time. You are talking about billions of dollars in losses. So Gilead will have to evaluate its options to either partner with them or buy CYDY out.
I will give you an example:
For instance way before Avalanche Biotech AAVL failed its phase 2 macular degeneration trial, Regeneron (REGN)had made a deal where it would pay for cost of trials and option to buy the entire program. why did Regeneron do this?
Had the AAVL macular degeneration program been successful it would have eaten into Eylea's (macular degeneration drug current standard of care) profits. So for Regeneron to protect itself it had a stake there just in case it was successful. Of course in the end it wasn't therefore Regeneron chose the option not to buy the program. Anyways Avalanche now merged with another company to become Adverum Biotechnologies.
The point remains here with CYDY. Gilead will have to do something to protect its 44% yearly HIV revenue.
That's not really shocking is it? They have no money, they had to put ESS trial on hold for many months and have still not started it yet. Anyways CEO making all the wrong moves personally he doesn't know how to run a biotechnology company either let his dad lead or give the position to someone that knows what they are doing.
If I was Amarantus CEO?
1. I would have cut out lympro and MS precise. Sold those assets if possible and unload them to someone else.
2. Company was built on Alzheimer's not ESS. I would have put focus on Eltoprazine for Alzheimer's ADHD, and Parkinsons LID. If they just advanced those assets they could have possibly been in phase 3 trials by now.
3. Found better financing, heck even Lincoln Park Capital, which is still not that great would have been better. Make a better deal with them, and forget about Josh Sason and his toxic cronies.
Where the heck is Gerald's father in all this? Why is he staying back not doing anything? Is he part of this rigged biotech? The board of directors need to get their heads out and remove Gerald as CEO.
Hey guys I did some Due Diligence on RXII and wrote an entire report. If you like and are interested in my joining my google group Helios Biotech Research Stock Picks" you are more than welcome to.
https://groups.google.com/forum/#!topic/helios-biotech-research/hzmOOrOe1Rc
I would probably wait to see how low this drops first. I have powder but I want to start to see an uptrend first back to $1.15 then buy a lot of shares. Although, if it drops significantly right before June 20th, I will then load the boat right before the phase 2b results.
Guys Relax, things are happening, all will be good soon.
Cytodyn still ahead if you look at in terms of where each company is. The approval that Taimed is seeking is for intravenous administration so at the hospital twice a month. Cytodyn Pro 140 is subcutaneous once a week at home self treatment.
It says that Taimed also working on intramuscular drug but that is not in the same stage as Cytodyn.
Pretty good results only one problem is that it is still only given in the hospital setting through an IV, nowhere near the same as home treatment option of Pro 140.
Not really just waiting for Judgement day coming up June 20th. Accumulating as much as I can before then! Other than that no need to say much.
Gilead will buy the company if the phase 2 results are good. And good things coming to CYDY.
Either way the point remains if the company they merge with is a private biotech company or public the combined company will have enough cash to run the pipeline. I don't understand what you are trying to get at?
With the merger or partnership with upfront money
You are correct, because they got the slot with all the journalists. The slot they got is a premier slot with a large group of journalists. Once the results are shown and very positive, I expect every journalist to write up a news story in the media. Gilead will be at the conference anyways so they are gonna get a first look into the results as well.
Side effects:
build-up of an acid in your blood (lactic acidosis), which is a serious medical emergency. Symptoms of lactic acidosis include feeling very weak or tired, unusual (not normal) muscle pain, trouble breathing, stomach pain with nausea or vomiting, feeling cold especially in your arms and legs, feeling dizzy or lightheaded, and/or a fast or irregular heartbeat
Serious liver problems. The liver may become large (hepatomegaly) and fatty (steatosis). Symptoms of liver problems include your skin or the white part of your eyes turns yellow (jaundice), dark “tea-colored” urine, light-colored bowel movements (stools), loss of appetite for several days or longer, nausea, and/or stomach pain
You may be more likely to get lactic acidosis or serious liver problems if you are female, very overweight (obese), or have been taking STRIBILD for a long time. In some cases, these serious conditions have led to death. Call your healthcare provider right away if you have any symptoms of these conditions
Worsening of hepatitis B (HBV) infection. If you also have HBV and stop taking STRIBILD, your hepatitis may suddenly get worse. Do not stop taking STRIBILD without first talking to your healthcare provider, as they will need to monitor your health. STRIBILD is not approved for the treatment of HBV
That is the Once a day HIV pill from Gilead you are talking about!
Also it gets worse:
Serious side effects of STRIBILD may also include:
New or worse kidney problems, including kidney failure. Your healthcare provider should do regular blood and urine tests to check your kidneys before and during treatment with STRIBILD. If you develop kidney problems, your healthcare provider may tell you to stop taking STRIBILD
Bone problems, including bone pain or bones getting soft or thin, which may lead to fractures. Your healthcare provider may do tests to check your bones
Changes in body fat can happen in people taking HIV-1 medicines
Changes in your immune system. Your immune system may get stronger and begin to fight infections. Tell your healthcare provider if you have any new symptoms after you start taking STRIBILD
Yah but would existing patients want to take 7 pills everyday 7 days a week? That's 49 pills per week and that is damaging on the liver.
Or would it be more prudent to take one weekly injection with Pro 140? With no toxicity, and no liver damage.
If you look up Truvada from Gilead sciences and other HIV pill drugs the number one concern is liver toxicity, nausea, vomiting, etc. Why go through all that when you can take Pro 140? IMO even existing patients will switch
Another article mentioning Charlie Sheen in Pro 140 drug trial and feeling better.
http://www.channel24.co.za/Gossip/News/new-hiv-drug-trial-has-charlie-sheen-feeling-amazing-20160520
I think you may or may not be right. But either way the phase 2b monotherapy results in June 20th IMO will move the share price higher. How much higher? Nobody can predict that, but it should move the needle by a huge margin. I'm more concerned though about a partnership or buyout. Because if the phase 2b monotherapy results are good , Gilead sciences will buyout the company to protect its 44% yearly HIV revenue in the billions. They won't sit on this trust me.!
Read the end of that article. It says that Gilead combined treatments and that treatment is almost similar to the current one. Gilead did that to protect its patent which is set to expire.
That's why I believe Gilead will buy Cytodyn pending good HIV results. Cytodyn has patient out by many years. That means Gilead won't have to worry about generics if it acquires Pro 140 until 15 to 20+ years.
Eyes on the prize buddy, the June 20th results is what will get this going. To the point of many saying why the abstract didn't move the stock its because the company couldn't release detailed results.
These results are for the monotherapy portion of the study. That means patients can ditch their ART regimen and only need to stay on Pro 140 to keep viral suppression. This is huge, and I am happy to be a long-term holder here. I am keeping my eye on the prize phase 3 data and possibly FDA approval.
How is this for prestigious for you? Gilead Sciences is making 7 presentations about HIV at the conference. I guess according to that Seeking alpha Author that's not prestigious lol.
One was relcoated, the other 2 probably didn't achieve full virological response. I'm just guessing but we shall see when the june 20th conference is out.
Actually one patient just relocated. Not that he didn't get full virological suppression
titan forget it, I already posted this many times, yet I still see the same thing about the company not posting the entire results? I have stated many times that the company can't release info until June 20th 2016, yet people don't listen or read.
Tang didn't short the stock. Tang just kept converting preferred shares to common shares then selling stock for quick profit. They just wanted instant gratification. Now I'm weary of Tang Capital and will not invest in any other company they are involved with.
Any company they touch they leave it toxic. For instance LJPC hit a 52-week high of $44.95 and now trades at $15 per share.
Heron Therapeutics hit a hit of 52-week high of $42.25 and now trades at $17 per share.
Point is that Tang is toxic they just enter a company and then sellout big to make instant profit. In the process they take the share price of the company lower. I have learned my lesson and any other stock Tang is invested in I will avoid.
That depends on when an investor bought shares. If they bought before the reverse split they are out with no chance to recover money.
For example lets say an investor bought 100,000 shares at 0.08 cents before the reverse split.
With the first reverse split of 1 for 150 that would mean the investor would now own 667 shares.
Now the company intends to do another 1 for 150 reverse split in June/July 2016. Another reverse split would bring the shareholders total shares to:
5 shares left.
so taking a look at 100,000 shares initially bought at 0.08 cents would mean the person spent a total of $8,000.
With 5 shares of AMBS an investor would have to wait for the stock to hit $1,600 dollars per share just to break even. There is no way this is a gold mine, not even by a long shot. It's more like a money grinder.
The company agreed that it wouldn't release detailed results until the June 20th ASM Microbe conference. That means what you see here is a summary or Abstract of all the info. But detailed info can't be revealed until the day of the presentation. The company is embargoed from releasing any data on this trial until the conference.
But management knows the value of the company they won't sell it for only $100 million.
Here is what my belief is. The company announced that it is working on a merger agreement. So therefore I think they will merge with another small cap biotechnology company.
The company I'm leaning towards is Foamix Pharmaceuticals (FOMX) because it is dermatology and also uses topical drug candidates to treat sever to moderate acne and Rosacea. It also has $108 million in cash.
Therefore the combined companies would be beneficial because they both work with topical gels, both dermatology companies, and it would bring more cash to the table along with cosmecueticals. It will be a merger like that, not an acquisition. I don't see the company selling itself for only $100 mil when management knows its worth at least $500 mil or more.
I agree with you sir. They don't stop the study at all. If anything this will increase recruitment rate in the trial.